The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who …
Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children under 15 years old and is the most common childhood cancer in the US1. Effective treatment options for patients with r/r …
The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are not eligible for treatment with another tyrosine kinase inhibitor. The approval indication also includes adults with T3151-positive CML and T3151-positive … Continue reading "FDA Grants Iclusig® Expanded Approval for CML"
Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab) to standard chemotherapy. ALL in children is a malignant disease, or cancer of the blood, characterized by the rapid uncontrolled growth of abnormal, … Continue reading "Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia"
The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to prior therapy. These results were recently published in the New England Journal of Medicine. Acute lymphoblastic leukemia (ALL) is an aggressive form of leukemia with limited treatment options once it progresses … Continue reading "Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia"
The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior therapies. These results were presented at a presidential symposium at the 2016 annual European Hematologic Association (EHA) meeting. Acute lymphoblastic leukemia (ALL) is the most aggressive … Continue reading "Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia"
The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These results were published as an early release article in the Journal of Clinical Oncology. Acute lymphoblastic leukemia (ALL) is a fast-growing form of leukemia, and is a common type of … Continue reading "Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia"
Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in … Continue reading "Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia"